EOJOAM
KLRS

E. Ohman J:or Asset Management’s Kalaris Therapeutics KLRS Stock Holding History

E. Ohman J:or Asset Management’s Portfolio KLRS Stock Details KLRS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-3,965
Closed -$1.18M – 454
2021
Q4 		$1.18M Buy
3,965
+817
+26% +$379K 0.03% 272
2021
Q3 		$1.81M Buy
+3,148
New +$1.46M 0.06% 194

Other funds holding KLRS

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
AIG
American International Group New York $609M AUM 23.67% 1-Year Est. Return
GC
GMT Capital Atlanta, Georgia $2.19B AUM 72.3% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
Massachusetts Financial Services
Massachusetts Financial Services Boston, Massachusetts $298B AUM 21.96% 1-Year Est. Return

E. Ohman J:or Asset Management's KLRS Position: Q1 2022 in Review

E. Ohman J:or Asset Management sold out of Kalaris Therapeutics (KLRS) in Q1 2022, closing a stake of 3,965 shares — an estimated $1.18M sold.

E. Ohman J:or Asset Management first reported a position in KLRS in Q3 2021 and held it in 2 quarters. The position peaked at $1.81M in Q3 2021. 84 funds tracked by Wall St. Rank hold KLRS as of Q1 2022.

  • E. Ohman J:or Asset Management reported no remaining Kalaris Therapeutics position as of Q1 2022 after selling out during the quarter.
  • E. Ohman J:or Asset Management sold 3,965 Kalaris Therapeutics shares in Q1 2022, an estimated $1.18M.
  • E. Ohman J:or Asset Management first reported a position in Kalaris Therapeutics in Q3 2021 and held it in 2 quarters.
  • E. Ohman J:or Asset Management's Kalaris Therapeutics position peaked at $1.81M in Q3 2021.
  • 84 funds tracked by Wall St. Rank held Kalaris Therapeutics as of Q1 2022.

Based on E. Ohman J:or Asset Management's 13F filing for Q1 2022, filed 5 Apr 2024.